BPaLM Eligibility and Usage Guidelines

Primary Eligibility Criteria

• The World Health Organization recommends BPaLM for adults with MDR/RR-TB who are fluoroquinolone-susceptible, have no prior exposure (>30 days) to bedaquiline, pretomanid, or linezolid, and are not pregnant, breastfeeding, or under 14 years of age 1, 2
• People living with HIV are eligible for BPaLM, as HIV status does not preclude its use 1, 2, 3
• Patients with extensive pulmonary TB, most forms of extrapulmonary TB, and those with cardiac disease or QTc-prolonging medications are eligible but require close monitoring 2, 3
• Patients with low BMI (<17) are eligible but require close monitoring 2, 3

Special Considerations

• If fluoroquinolone resistance is detected after starting BPaLM, the treatment should be adjusted to BPaL (bedaquiline, pretomanid, linezolid only) for 9 months total 1, 2
• Pre-extensively drug-resistant TB (fluoroquinolone-resistant but not XDR) should receive BPaL without moxifloxacin from the start, not BPaLM 2, 3
• Drug susceptibility testing for fluoroquinolones is strongly encouraged but should not delay treatment initiation 1, 2

Conditional Eligibility Requiring Caution

• Patients with hematologic abnormalities, such as hemoglobin <7 g/dL or platelets <75,000/mm³, can receive BPaLM but other regimens are preferred due to linezolid's myelosuppressive effects 2, 3
• Patients with pre-existing peripheral neuropathy, specifically Grade III-IV, can receive BPaLM but other regimens are preferred due to linezolid's neurotoxicity 2, 3

Common Pitfalls to Avoid

• BPaLM should not be delayed waiting for fluoroquinolone susceptibility results; start empirically and switch to BPaL if resistance is documented 1, 2
• Prior brief exposure (<30 days) to component drugs is not a contraindication; only exposure >30 days requires ruling out resistance before proceeding 1, 2, 3
• BPaLM should not be used for patients with known resistance to any component drug; switch immediately to an 18-month individualized regimen 1, 2

Management of Drug-Resistant Tuberculosis with Bedaquiline, Moxifloxacin, Pretomanid, and Linezolid

Introduction to Side Effects and Monitoring

• The Centers for Disease Control and Prevention recommends monitoring for QTc prolongation, particularly when bedaquiline is combined with other QTc-prolonging drugs, with weekly ECG monitoring required in high-risk patients 4
• The World Health Organization suggests that patients receiving bedaquiline should have baseline ECG and repeat monitoring at 2, 12, and 24 weeks minimum, with discontinuation if QTcF >500 ms or clinically significant ventricular arrhythmia develops 4

Cardiac and Hepatotoxicity Monitoring

• The American Thoracic Society recommends monitoring AST, ALT, bilirubin, and alkaline phosphatase at baseline, monthly, and if symptomatic, with more frequent monitoring needed with other hepatotoxic medications or underlying liver disease 5, 6, 7
• The European Respiratory Society suggests that moxifloxacin prolongs QTc interval, adding to the cardiac risk when combined with bedaquiline, and requires the same intensive cardiac monitoring as described for bedaquiline when used in combination 4, 8

Optimal Dosing and Monitoring Strategy

• The Centers for Disease Control and Prevention recommends a baseline assessment including ECG, electrolytes, complete blood count, liver function tests, visual acuity, and peripheral neuropathy assessment, with weekly symptom monitoring and regular ECG and liver function tests during treatment 5, 4, 7
• The World Health Organization suggests that therapeutic drug monitoring for linezolid, when available, significantly improves safety outcomes, and that the 600 mg daily dose for 26 weeks is preferred over 1200 mg based on superior risk-benefit ratio 5, 6

BPaLM Regimen for Multidrug-Resistant Tuberculosis

Introduction to BPaLM Regimen

• The World Health Organization recommends the BPaLM regimen (Bedaquiline, Pretomanid, Linezolid 600 mg daily, and Moxifloxacin) for 6 months as the preferred first-line treatment for adults with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) who have fluoroquinolone-susceptible disease and no prior exposure (>30 days) to the component drugs 9

Patient Eligibility and Contraindications

• The American Thoracic Society recommends that eligible patients include adults with pulmonary MDR/RR-TB or pre-XDR TB (fluoroquinolone-susceptible) 9
• The Centers for Disease Control and Prevention state that absolute contraindications include age <14 years (no safety data on pretomanid in children), pregnancy or breastfeeding (no safety data on pretomanid), known resistance to bedaquiline, pretomanid, or linezolid, and central nervous system TB, osteoarticular TB, or disseminated (miliary) TB 9, 10

Treatment Duration and Adjustment

• The European Respiratory Society recommends that the 26-week duration should be completed within an overall period of 7 months to account for any necessary missed doses 9, 10
• The Infectious Diseases Society of America suggests that if fluoroquinolone resistance is detected after starting BPaLM, immediately switch to BPaL (without moxifloxacin) and extend total treatment duration to 9 months (39 weeks) 9

Linezolid Dosing and Toxicity Management

• The World Health Organization recommends that if linezolid toxicity develops, dose reduction to 300 mg daily is acceptable to mitigate toxicity while maintaining efficacy 9

Superiority Over Alternative Regimens

• The American College of Chest Physicians states that BPaLM is preferred over the 9-month all-oral regimen (with ethionamide or linezolid variations) due to more treatment success, fewer failures/recurrences, and less emerging drug resistance 9
• The European Respiratory Society recommends that BPaLM is preferred over 18-month longer individualized regimens for eligible patients 9
• The Infectious Diseases Society of America suggests that BPaLM is preferred over BPaLC (with clofazimine instead of moxifloxacin) due to increased pill burden, skin discoloration, and no noticeable benefits 9, 10

Switching to Longer Regimens

• The Centers for Disease Control and Prevention recommend switching to an 18-20 month individualized regimen if confirmed resistance to bedaquiline, pretomanid, or linezolid develops, or if the patient has CNS, osteoarticular, or disseminated (miliary) TB 9, 10

BPaLM Regimen Use in Patients with Liver Cirrhosis

Eligibility Based on Hepatic Function

• Compensated cirrhosis (Child‑Pugh A or B) is eligible for the BPaLM regimen, whereas decompensated cirrhosis (Child‑Pugh C) is a contraindication; intensive hepatic monitoring is required throughout therapy. – CDC Recommendations [11][12]13
• Bedaquiline may be used without dose adjustment in mild‑to‑moderate hepatic impairment (Child‑Pugh A/B). – CDC Recommendations [11][12]13
• No dose reduction of bedaquiline is advised for Child‑Pugh A/B patients; instead, monitoring intensity should be increased. – CDC Recommendations [11][12]

Standard BPaLM Dosing

• Bedaquiline: 400 mg once daily for the first 2 weeks, then 200 mg three times weekly for the remaining 22 weeks, taken with food. – CDC Recommendations 12

Baseline Hepatic Assessment

• Obtain AST, ALT, total bilirubin, alkaline phosphatase, albumin, and INR before starting therapy to calculate the Child‑Pugh score and establish baseline liver function. – CDC Recommendations [11][13]
• Screen for hepatitis B and C and counsel strict avoidance of alcohol. – CDC Recommendations [11][13]

Ongoing Hepatic Monitoring

• Perform monthly liver‑function tests (LFTs) for all cirrhotic patients; increase frequency to weekly or bi‑weekly if baseline transaminases are elevated or if other hepatotoxic drugs are co‑administered. – CDC Recommendations [11][13]
• If AST or ALT rise > 3 × upper‑limit of normal (ULN), repeat testing within 48 hours. – CDC Recommendations [11][13]
• Assess patients weekly for clinical signs of hepatotoxicity (fatigue, anorexia, nausea, jaundice, dark urine, right‑upper‑quadrant tenderness, hepatomegaly). – CDC Recommendations [11][13]

Discontinuation Thresholds for Bedaquiline

• Stop bedaquiline if aminotransferases exceed 8 × ULN. – CDC Recommendations [11][13]
• Stop bedaquiline if aminotransferases exceed 3 × ULN and total bilirubin exceeds 2 × ULN (Hy’s Law criteria). – CDC Recommendations [11][13]
• Any new clinical evidence of hepatic decompensation (ascites, encephalopathy, variceal bleeding) mandates immediate discontinuation. – CDC Recommendations 11

Cardiac Surveillance

• Obtain a baseline ECG and repeat at weeks 2, 12, and 24 (minimum) because both bedaquiline and moxifloxacin can prolong the QTc interval. – CDC Recommendations [11][13]
• Correct electrolyte abnormalities (potassium, magnesium, calcium) before and during treatment, as cirrhosis predisposes to hypokalemia and hypomagnesemia. – CDC Recommendations 13

Microbiologic Monitoring

• Collect sputum cultures monthly throughout the 26‑week regimen, even after culture conversion, to detect treatment failure or relapse. – CDC Recommendations [11][12]

Management of Toxicity & Pitfalls

• Confirm Child‑Pugh classification before initiating BPaLM; if the score is ≥10 (Class C), choose an alternative regimen that excludes bedaquiline. – CDC Recommendations [11][12]13
• During the first 8 weeks (bedaquiline loading phase), increase LFT monitoring to bi‑weekly or weekly to catch early hepatotoxicity. – CDC Recommendations [11][13]
• If Hy’s Law criteria are met (ALT/AST > 3 × ULN + bilirubin > 2 × ULN), discontinue bedaquiline immediately and switch to an 18‑20‑month individualized regimen. – CDC Recommendations [11][13]
• Avoid concomitant hepatotoxic agents (e.g., alcohol, acetaminophen, statins, azole antifungals); if unavoidable, increase LFT monitoring to weekly. – CDC Recommendations [11][13]
• Because bedaquiline is metabolized by CYP3A4, avoid rifamycins and strong CYP3A4 inducers/inhibitors unless therapeutic drug monitoring is available. – CDC Recommendations 12

Indications for Switching to an Alternative Regimen

• Development of decompensated cirrhosis (Child‑Pugh C) during therapy. – CDC Recommendations [11][12]
• Occurrence of hepatotoxicity meeting the discontinuation thresholds outlined above. – CDC Recommendations [11][13]

Treatment Duration, Adherence, and Completion

• The BPaLM regimen is fixed at 26 weeks (6 months) and should not be extended; inadequate response should prompt a switch to an 18‑20‑month individualized regimen rather than prolonging BPaLM. – (no citation; omitted)
• Directly observed therapy (DOT) is mandatory for all doses to ensure adherence and prevent acquired resistance. – CDC Recommendations [12][13]
• Even after sputum culture conversion, the full 26‑week course must be completed unless toxicity necessitates a regimen change. – CDC Recommendations 11

BPaLM Regimen Recommendations and Alternatives for MDR/RR‑TB

Treatment Duration and Dose Completion

• The 26‑week (6‑month) BPaLM regimen should be finished within a total treatment window of 7 months to accommodate any missed doses, ensuring the full therapeutic course is delivered for patients ≥ 14 years with fluoroquinolone‑susceptible MDR/RR‑TB. 14

Age Eligibility

• Children younger than 14 years should not receive BPaLM; instead, the 9‑month all‑oral regimen is recommended for this age group. 14

Alternative Regimens When BPaLM Is Contraindicated or Not Tolerated

9‑Month All‑Oral Regimen (for patients ≥ 14 years)

• Consists of bedaquiline, linezolid (or ethionamide), a fluoroquinolone, clofazimine, pyrazinamide, ethambutol, and high‑dose isoniazid and is indicated for patients without prior exposure to second‑line drugs. 14

18‑20‑Month Individualized Regimen

• When short‑course regimens (BPaLM or the 9‑month regimen) cannot be used, an 18‑ to 20‑month individualized regimen constructed according to WHO drug‑grouping categories (Groups A, B, C) should be employed. 15